doxorubicin hydrochloride / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   643 Trials   643 Trials   26774 News 


«12...455456457458459460461462463464465...522523»
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Clinical, Journal:  A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy. (Pubmed Central) -  Feb 1, 2019   
    In addition, loaded into pHCT74-lipo, doxorubicin demonstrated significantly improved anti-tumour activity on prostate tumour-bearing mice. These results suggest that the pHCT74 peptide has potential to be used in the development of a novel drug delivery system for targeted therapy against prostate cancer.
  • ||||||||||  plinabulin (BPI 2358) / BeyondSpring
    Trial completion date, Trial primary completion date:  PROTECTIVE-2: Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia (clinicaltrials.gov) -  Jan 31, 2019   
    P2/3,  N=237, Recruiting, 
    Trial completion date: Jul 2019 --> May 2021 | Trial primary completion date: Jul 2019 --> May 2021 Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Oct 2018 --> Jan 2020
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  LCI-SAR-STS-PEM-001: Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma (clinicaltrials.gov) -  Jan 30, 2019   
    P2,  N=30, Recruiting, 
    Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Oct 2018 --> Jan 2020 Trial completion date: Feb 2019 --> Feb 2025 | Trial primary completion date: Feb 2019 --> Jul 2020
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Trial completion date, Trial primary completion date, Combination therapy:  Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) -  Jan 29, 2019   
    P1/2,  N=50, Recruiting, 
    Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Nov 2018 --> Sep 2025 Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Biomarker, Journal, Tumor microenvironment:  Design of tumor microenvironment responsive drug-drug micelle for cancer radiochemotherapy. (Pubmed Central) -  Jan 28, 2019   
    The Fe-NI micelles successfully encapsulate the hydrophobic chemotherapy drug doxorubicin (DOX) and are modified with hyaluronic acid (HA) by electrostatic interactions to form HA-Fe-NIs-DOX micelles...The HA-Fe-NIs-DOX micelles show a significant radiosensitizing effect on the tumors and the combination of chemotherapy and radiotherapy (RT) is realized for the treatment of tumor in vitro and vivo. These findings illustrate that HA-Fe-NIs micelles are a promising candidate, which enhances the antitumor effects as a DOX delivery system, owing to the synergistic mechanisms of antitumor agents and chemo-/radiotherapy.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Clinical, Journal:  Neoadjuvant chemotherapy for radiation-associated soft-tissue sarcoma: A case report. (Pubmed Central) -  Jan 27, 2019   
    In this case, doxorubicin plus ifosfamide chemotherapy was employed with a favorable therapeutic effect prior to being resected. To our knowledge this is the first report of greater than 90% necrosis in a patient with radiation-associated undifferentiated/unclassified soft-tissue sarcoma treated with chemotherapy for a borderline resectable mass.
  • ||||||||||  Fibromun (onfekafusp alfa) / Philogen
    Enrollment open, Trial initiation date, Metastases:  Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) (clinicaltrials.gov) -  Jan 23, 2019   
    P2,  N=114, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Dec 2018
  • ||||||||||  Trial completion, Enrollment change, Trial completion date:  PBIC: Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens (clinicaltrials.gov) -  Jan 22, 2019   
    P=N/A,  N=35, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Dec 2018 Active, not recruiting --> Completed | N=50 --> 35 | Trial completion date: Jul 2017 --> Mar 2016
  • ||||||||||  cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Clinical, Journal:  Orthotopic Liver Transplantation After Stereotactic Body Radiotherapy for Pediatric Hepatocellular Carcinoma with Central Biliary Obstruction and Nodal Involvement. (Pubmed Central) -  Jan 18, 2019   
    After completing radiotherapy, his total bilirubin level fell below 1.0 mg/dL, allowing him to begin systemic therapy with cisplatin and doxorubicin. At three months after SBRT, his bilirubin was 0.1 mg/dL, alpha-fetoprotein (AFP) was 88 ng/mL, and imaging demonstrated a decrease in tumor size (total volume 28.7 cc), with no evidence of local or distant disease progression. He then developed distant disease within the liver, but his disease remained controlled at the primary site and nodes that had been treated with SBRT. He underwent orthotopic liver transplantation (OLT) with an uneventful operative course and remains with no evidence of disease at seven months after OLT. This is one of the first reported cases of successful downstaging of pediatric HCC with nodal involvement to allow for OLT, and it argues for consideration of similar patients for OLT.
  • ||||||||||  chloroquine phosphate / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Preclinical, Journal:  Co-delivery Nanoparticles of Doxorubicin and Chloroquine for Improving the Anti-cancer Effect in vitro. (Pubmed Central) -  Jan 17, 2019   
    It can be concluded that the system can prevent the drug from being recognised and excluded by P-gp, and CQ blocks the process of autophagy so that the DOX is protected and more distributed to the nucleus of multidrug resistance (MDR) cell. The NPDOX+CQ constructed in this study provides a feasible strategy for reversing MDR in tumour cells.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion:  Preoperative Herceptin and Navelbine for Breast Cancer (clinicaltrials.gov) -  Jan 16, 2019   
    P2,  N=49, Completed, 
    The NPDOX+CQ constructed in this study provides a feasible strategy for reversing MDR in tumour cells. Active, not recruiting --> Completed
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Biomarker, Review, Journal, IO biomarker:  Risk-adapted therapy for advanced-stage Hodgkin lymphoma. (Pubmed Central) -  Jan 11, 2019   
    Improved methods to assess higher risk at diagnosis using quantitative PET metrics, such as metabolic tumor volume and total lesion glycolysis, and incorporation of emerging biomarkers may further refine patient selection for more intensive upfront therapy. The ultimate goal is to achieve the highest level of efficacy for an individual patient while minimizing the short- and long-term toxicities.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Adcetris (brentuximab vedotin) / Seagen, Takeda, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Where does PD-1 blockade fit in HL therapy? (Pubmed Central) -  Jan 11, 2019   
    Subsequent studies have evaluated novel anti-PD-1-based combination regimens as well as the use of anti-PD-1 antibody therapy earlier in the course of a HL patient's therapy, including first salvage therapy for rel/ref disease (eg, nivolumab plus brentuximab vedotin) and even first-line treatment (eg, nivolumab added to doxorubicin, vinblastine, dacarbazine chemotherapy). The current role of PD-1 blockade in HL is as monotherapy in patients with advanced rel/ref disease, but the results of ongoing studies and the evolving treatment landscape in HL will determine the role of PD-1 blockade in the future.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound (clinicaltrials.gov) -  Jan 10, 2019   
    P=N/A,  N=10, Active, not recruiting, 
    Targeting collagen P4H is a promising strategy to inhibit tumor progression and sensitize TNBC to chemotherapeutic agents. Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Enrollment open:  CineDoxo: Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE (clinicaltrials.gov) -  Jan 10, 2019   
    P4,  N=10, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Enrollment closed, Trial primary completion date:  Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer (clinicaltrials.gov) -  Jan 9, 2019   
    P1/2,  N=61, Active, not recruiting, 
    Therefore, the differential responses observed with CD47 blockade are due to autonomous activation of protective autophagy in normal tissue and enhancement immune cytotoxicity against cancer cells. Trial primary completion date: Oct 2018 --> Oct 2019 | Recruiting --> Active, not recruiting
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer (clinicaltrials.gov) -  Jan 3, 2019   
    P1,  N=79, Active, not recruiting, 
    Initiation date: Sep 2016 --> Jul 2017 Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Nov 2019 | Trial primary completion date: Jun 2019 --> Oct 2018
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Enrollment open, Metastases:  OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients (clinicaltrials.gov) -  Jan 3, 2019   
    P2,  N=60, Recruiting, 
    Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Not yet recruiting --> Recruiting
  • ||||||||||  bortezomib / Generic mfg.
    Biomarker, Clinical, Journal:  Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. (Pubmed Central) -  Jan 2, 2019   
    Pretreatment serum samples were obtained from 61 proteasome inhibitor-naive, transplant-eligible patients who were eligible for salvage PAD (bortezomib, doxorubicin, and dexamethasone) or VTD (bortezomib, thalidomide, and dexamethasone) chemotherapy...Among the identified proteins were apolipoprotein C1, complement components and sulfhydryl-oxidase 1.  CONCLUSIONS    The results demonstrate that label-free proteomic analysis is a useful method to describe proteins differentially expressed in the sera of MM patients. Further studies are needed to analyze the use of identified proteins as biomarkers.